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Abstract
This review focuses on smoking cessation treatments for peo-
ple with schizophrenia spectrum disorders. It concludes with com-
ments on the significance of the research and why it constitutes an
original contribution. We searched PubMed (National Library of
Medicine), and PsycINFO (Ovid) (2006-2020) for studies on
schizophrenic disorder (schizophrenia or psychotic or psychosis
or severe mental illness) and smoking cessation treatment (smok-
ing cessation treatment or varenicline or tobacco cessation or
reduction or bupropion or NRT or behavioral treatment or e-ciga-
rette). Studies found evidence suggesting that pharmacotherapy
combined with behavioural therapy for smoking cessation is
effective amongst smokers with schizophrenia spectrum disorders,
although more long-term research is required. This review sum-
marised and critically reviewed also studies on vaping as a smok-
ing cessation strategy for smokers with schizophrenia spectrum
disorders and evidence suggests that they may effective as smok-
ing cessation tool and may be less harmful alternatives to com-
bustible cigarette smoking. Consequently, e-cigarettes could be
considered as an applicable instrument for Tobacco Harm
Reduction (THR) and smoking cessation. Overall, there are very
few studies of e-cigarettes for smoking cessation in patients with
schizophrenia and these studies are very small. They have promis-
ing results, but more research is needed. 
Background
Tobacco smoking among people with mental illness is signif-
icantly higher than in the general population. Tobacco smoking
has negative effects on physical, mental and financial well-being
of people with mental illness (Molla et al., 2017). In people with
schizophrenia spectrum disorder, the risk of mortality is doubled
(Bitter et al., 2017). About 50% of deaths in patients with chronic
mental illness are due to tobacco related cancers, respiratory dis-
eases, and cardiovascular conditions (Callaghan et al., 2014; Kelly
et al., 2011) and among smokers with schizophrenia spectrum,
smoking is associated with depressive symptoms, increased hos-
pitalizations, stress, poor treatment outcomes, low quality of life,
and enhanced psychotic symptoms (Dixon et al., 2007). Although
smoking rates are declining in the general population in developed
countries (Shafey et al., 2010), patients with long-standing mental
health disorders are almost twice as likely to smoke as people
without such problems (Banham, 2010). Smoking prevalence
rates among people with mental disorders are two to four times
higher than in the general population (Tidey, 2005). Prevalence is
greatest in patients with schizophrenia with rates around 64% fol-
lowed by patients with bipolar disorder, with rates around 44%
(Dickerson et al., 2013). Smokers affected by schizophrenia spec-
trum disorders show an increase in rates of smoking and nicotine
dependence relative to non-affected smokers. One possible reason
for this phenomenon is that these patients smoke traditional
cigarettes to stimulate their cognitive performance and several
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studies have conducted to assess the impact of nicotine intake on
cognitive function in people with schizophrenia spectrum disorder
(D’Souza & Markou, 2012). However, the reasons for the high fre-
quency of both high nicotine dependence and high smoking preva-
lence in patients with schizophrenia spectrum disorders are incom-
pletely understood. Illness related factors, symptoms of illness fac-
tors, patient related factors and health service related barriers fac-
tors have been considered in an attempt to find a reason for the
relationship between high smoking rates and schizophrenia but
have failed to arrive at decisive conclusions. Environmental and
genetic aspects play roles in the aetiology and progress of nicotine
addiction and schizophrenia. Patient affected by schizophrenia
have abnormal expression of certain genes which are common to
nicotine addiction and schizophrenia disorder (Riley et al., 2000;
Mexal et al., 2010; Purcell et al., 2014; Owen Sawa & Mortensen,
2016). However, this does not completely explain the high smok-
ing rates in smokers with schizophrenia spectrum disorders. Baker
et al. (2007) reported that, compared to general population sam-
ples, persons affected by schizophrenia spectrum disorders were
more likely to indicate that addiction, stimulation and stress man-
agement were reasons for smoking traditional cigarettes.
McCloughen (2003) suggested that high smoking rates and high
nicotine dependence in smokers with schizophrenia are explained
by personal and social factors, many people with schizophrenia
spectrum disorder are unemployed and inactive, and smoking was
reported to relieve boredom and improve low self-esteem.
Kelly et al. (2012) examined the perceived consequences and
benefits of cigarette smoking and motivation for quitting in 100 no
treatment-seeking smokers who had schizophrenia or schizoaffec-
tive disorder and 100 people without a psychiatric disorder. People
with schizophrenia reported that cigarette smoking made socialis-
ing easier compared with the control group. They also had a lower
appreciation for health risks associated with cigarette smoking
than controls. Potential health consequences were found to be a
less compelling reason to quit smoking compared with the control
group. Smoking cigarettes is frequently socially accepted among
smokers with schizophrenia spectrum disorders (Trainor &
Leavey, 2017; Twyman, Bonevski, Paul, & Bryant, 2014) and
many smokers with schizophrenia spectrum are not given smoking
cessation treatment from health professionals providers (Goldberg,
2010; Trainor & Leavey, 2017). Two researchers found that smok-
ers with schizophrenia spectrum were less likely to be advised to
quit compared with smokers without schizophrenia spectrum dis-
orders (Briskman, Bar, Boaz, & Shargorodsky, 2012; Duffy et al.
2012). Brown et al. (Brown et al., 2015) studied the perceptions of
mental health professionals in providing the “5 A’s” (ask, advise,
assess, assist, arrange) of smoking cessation advice to smokers
with schizophrenia. Clinicians rated their perceived lack of interest
among patients to initiate a smoking cessation treatment related to
too time demanding to carry out 5 A’s, insufficient staff and staff
scepticisms about the value of the 5 A’s as a great barriers prevent-
ing application of the 5 A’s. Health service and mental health pro-
fessionals have an important role in encouraging quit attempts and
can guide the application of smoking cessation treatment in clini-
cal practice (Prochaska, 2011) but several mental health profes-
sionals believe stopping smoking traditional cigarettes may worsen
their patients’ condition, and some mental health professionals’
feel that they are taking away one of their patients only
pleasures/enjoyment in life (Ratschen, Britton, Doody, Leonardi-
Bee, & McNeill, 2009; Johnson, Moffat, & Malchy, 2010) hence
health service and health professionals related barriers factors are
other possible reasons explaining high smoking rates in people
affected by schizophrenia spectrum disorders.
Materials and Methods
PubMed (National Library of Medicine), and PsycINFO
(Ovid) were searched with the assistance of a trained librarian
experienced in developing search strategies for reviews. Concepts
that made up the search were: smoking cessation and schizophre-
nia. The search was not restricted by language or geographical
region, and was carried out by combining an exhaustive list of
terms denoting schizophrenic disorder (schizophrenia or psychotic
or psychosis or severe mental illness) AND smoking cessation
treatment (smoking cessation treatment or varenicline or tobacco
cessation or reduction or bupropion or NRT or behavioural treat-
ment or e-cigarette). Additionally, reference lists of all included
papers were checked for any citations missed by electronic data-
base searching. Cohort and case-control study designs were con-
sidered eligible for inclusion. Cross-sectional studies, case series
and case reports were included. The publication dates were limited
to January 2006 to Febrary 2020. Relevant articles were also
searched in Scopus (Elsevier) to determine if they were cited by
studies that previous searches had not found. We identified 77 orig-
inal studies from the electronic search of the databases (39 studies
from PubMed and 38 from PsycINFO).
Licensed aids to smoking cessation in smokers
with schizophrenia spectrum
Actual licensed aids to smoking cessation in smokers with
schizophrenia spectrum disorders still yield low long-term absti-
nence rates (Cather, Pachas, Cieslak, & Evins, 2017) and a meta-
analytic study showed that for randomised controlled studies using
bupropion or bupropion combined with NRT, the odds of smoking
abstinence at six months were less than one in five participants
(Tsoi, Porwal, & Webster, 2013).
Nicotine replacement therapy
Seven studies evaluated NRT for smoking cessation in smok-
ers with schizophrenia spectrum disorders.
Four observational studies of open label NRT plus psychoso-
cial treatment with motivational interviewing and CBT compo-
nents have been conducted in smokers with schizophrenia. Three
studies in 24-65 outpatients found quit rates of 9-14% at six-month
follow-up assessments (Ziedonis & George, 1997; Addington, el-
Guebaly, Campbell, Hodgins, & Addington, 1998; George et al.,
2000) and one study in 68 outpatients found a 23% continuous
abstinence rate at three-month follow-up (Chou, Chen, Lee, Ku, &
Lu,2004). 
In the largest smoking study in this population, 298 outpatients
with a psychotic disorder (57% with schizophrenia) were ran-
domised to routine care or to 10 weeks of treatment with motiva-
tional interviewing and CBT plus NRT (Baker et al., 2006). At the
12 month follow-up assessment, abstinence was not significantly
higher in the treatment group (10.9%) compared with the control
group (6.6%) (OR 1.72, 99% CI 0.58 to 5.09), but significantly
more people in the treatment group had reduced the number of cig-
arettes they smoked each day by half (2.09, 99% CI 1.03 to 4.27).
In addition, authors affirmed that the study groups showed signif-
icant improvement as a whole on several mental health question-
naires and absence of exacerbations of psychotic symptoms, but
they used mental health questionnaires not specifically validated









for schizophrenia spectrum disorders.
One placebo-controlled study investigated the efficacy of NRT
for the prevention of relapse in smokers with schizophrenia (Horst,
Klein, Williams, & Werder, 2005). Fifty outpatients received nico-
tine patches that delivered 14-42 mg per day for 90 days along with
weekly group motivational support. Those who quit (36%) were
then randomised to continue receiving nicotine patches (same
dose) or to receive placebo patches, along with biweekly group
support, for another six months. At the end of this period, signifi-
cantly more people receiving NRT remained abstinent compared
with those receiving placebo (67% v 0%; P < 0.01). However, the
use of a high-level nicotine patch at 42 mg, although it can guar-
antee high levels of efficacy, makes the symptoms of nicotine over-
dose highly probable in cases where the subject continues to
smoke.
In a Cochrane review that included 11 NRT studies, Tsoi et al.
(2013) concluded that there is currently little evidence to support
the effectiveness of NRT in people with schizophrenia despite the
benefits in the general population.
Bupropion 
Eight studies evaluated bupropion for smoking cessation in
smokers with schizophrenia spectrum disorders.
Two placebo-controlled trials in 32 and 57 smokers with schiz-
ophrenia found that bupropion significantly increased continuous
abstinence during treatment (P<0.05), although these effects were
not maintained at the three to six-month follow-ups (George et al.,
2002; Evins et al., 2005). Two trials that compared bupropion plus
NRT with placebo plus NRT in smokers with schizophrenia found
that bupropion plus NRT significantly increased the odds of con-
tinuous abstinence during treatment but not at the three to 12
month follow-ups (D’Souza et al., 2012; Esterlis et al., 2013). 
In an observational study that examined the efficacy of extend-
ed open label bupropion plus NRT, 41 smokers with schizophrenia
received bupropion plus NRT (patch plus gum or lozenge) and
CBT for three months. At the end of this period, those who were
abstinent (42%) entered a 12 month relapse prevention phase with
bupropion plus NRT and CBT (Cather et al., 2013). At the 12
month assessment, 59% had achieved four weeks of continuous
abstinence. However, the four previous trials and the observational
study based their conclusions on studies that used small sample
sizes. A Cochrane review by Tsoi et al. (2013) found that bupropi-
on was associated with a three-fold increase in cessation in smok-
ers with schizophrenia (risk ratio 3.03, 1.69 to 5.42 at end of treat-
ment; 2.78, 1.02 to 7.58 at six months). In a recent systematic
review and meta-analysis conducted by Peckham, Brabyn, Cook,
Tew, and Gilbody, (2017), eight trials comparing bupropion with
placebo were pooled showing that bupropion improved quit rates
significantly in the medium and long term but not the short term
(short term RR=6.42 95% CI 0.82–50.07; medium term RR=2.93
95% CI 1.61–5.34; long term RR=3.04 95% CI 1.10–8.42). 
In the Evaluating Adverse Events in a Global Smoking
Cessation (EAGLES) study (Anthenelli et al., 2016), the largest
comparative study of licensed smoking cessation aids, 8,144
smokers of traditional cigarettes with or without a diagnosis of
psychiatric disorder used three months of treatment or placebo
with a further three months follow-up of non-treatment, showing
that bupropion has superior continuous abstinence rates vs. place-
bo at weeks 9-12 and 9-24 in both cohorts. 4,116 smokers were in
the psychiatric cohort and 9.5% were affected by schizophrenia
spectrum disorders. However, the continuous success rates at week
12 and week 24 were larger for people without diagnosis of psy-
chiatric disorders (week 12, 22.6%, week 24, 16.2%) compared
with participants with psychiatric disorders (week 12, 26.1%, week
24, 18.8%) and success rates were not stratified according to the
specific psychiatric diagnosis.
Varenicline
Seven studies evaluated varenicline for smoking cessation in
smokers with schizophrenia spectrum disorders.
A placebo-controlled trial (n=9) found that three in four smok-
ers with schizophrenia taking varenicline achieved continuous
abstinence during the last four weeks of the treatment period com-
pared with no patients taking placebo (P=0.14) and no increases
were seen in psychiatric symptoms or suicidal ideation (Weiner et
al., 2011). However, this research enrolled only nine participants,
of which eight completed the study, and specific validated ques-
tionnaires for schizophrenia spectrum disorders, such as SAPS,
SANS or PANSS, were not used to assess changes in schizophrenia
symptoms. A multi-site placebo-controlled trial of varenicline with
brief counseling in 128 smokers with schizophrenia found that
varenicline significantly increased point prevalence abstinence at
the end of treatment (19% v 4.7%; P<0.05) but not at the six month
follow-up (Barr, Procyshyn, Hui, Johnson, & Honer, 2008).
However, it is important to clarify that these patients undertook 12
weeks of treatment with varenicline and an extension of the use of
varenicline up to 24 weeks would have probably reduced relapse
rates at six month follow-up. In the study of Barr et al. (2008),
rates of adverse events (AEs) were similar across conditions, and
schizophrenia symptoms, assessed by SAPS and SANS scales,
were stable or decreased in both groups. 
Finally, a 10-site placebo-controlled trial investigated whether
varenicline reduces smoking relapse (Evins et al., 2014). In total,
247 patients with schizophrenia spectrum or bipolar disorder were
enrolled and 203, of which 185 (91%) with schizophrenia spec-
trum disorders, entered the open label treatment phase. Of these,
87 (43%) attained two weeks of continuous abstinence and entered
the relapse prevention phase, in which they were randomised to
varenicline or placebo with CBT. At week 52, point prevalence
abstinence rates were significantly higher in people taking vareni-
cline (60% vs. 19%; OR 6.2, 95% CI 2.2 to 19.2), and rates of con-
tinuous abstinence from week 12 to 76 were also higher (30% vs.
11%; 3.4, 1.02 to 13.6). Varenicline had no effect on psychiatric
symptoms. Two patients in each group reported suicidal ideation
during the maintenance phase but there were no suicide attempts.
Thus, amongst smokers with schizophrenia who attained absti-
nence, varenicline was well tolerated and increased prolonged
abstinence for as long as 76 weeks (Evins et al., 2014). However
as declared by the authors, smokers were enrolled from community
mental health centers so that the findings should be generalizable
to the large majority of patients with schizophrenia spectrum or
bipolar disorders who are cured in this kind of setting. 
The EAGLES study showed that varenicline has superior con-
tinuous abstinence rates vs. bupropion, NRT patch and placebo at
weeks 9-12 and 9-24 in smokers with and without a history of psy-
chiatric disorders with no significantly increased neuropsychiatric
safety risk vs. placebo (Anthenelli et al., 2016). However, the con-
tinuous success rates at week 12 and week 24 were larger for peo-
ple without diagnosis of psychiatric disorders (week 12, 33.5%;
week 24, 21.8%) compared with participants with psychiatric dis-
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orders (week 12, 38%; week 24, 25.5%) and success rates were not
stratified according to the specific psychiatric diagnosis.
The Cochrane review by Tsoi et al. (2013), found that vareni-
cline is associated with an almost five-fold increase in cessation
(4.74, 1.34 to 16.71 at end of treatment). In the review and meta-
analysis by Peckham, et al. (2017), five trials comparing vareni-
cline with placebo showed that the addition of varenicline
improved quit rates significantly in the medium term (RR=4.13,
95% CI 1.36–12.53). A network meta-analysis about the effective-
ness and tolerability of adjunctive pharmacotherapy for smoking
cessation in adults with serious mental illness (Roberts, Evins,
McNeill, & Robson, 2016) suggests that varenicline and bupropion
are effective and tolerable for smoking cessation in adults with
serious mental illnesses. A review by Kishi and Iwata (2015)
pooled five RCTs and found that varenicline performed no better
than placebo in achieving smoking cessation (RR 0.79, 95% CI
0.58–1.08, n=332); however, these authors combined findings of
studies where participants were recruited into studies to test
varenicline for health outcomes other than smoking
cessation/reduction.
Behavioural interventions
Bennett, Wilson, Genderson, and Saperstein (2013) identified
11 studies investigating behavioural therapies in people with schiz-
ophrenia and found that in the short term these had good post-treat-
ment abstinence rates of up to 42%. In addition, Bennett et al.
(2013) found that these interventions were well tolerated by people
with schizophrenia and found no evidence of deleterious impact on
psychiatric symptoms. 
A study of 87 people compared higher versus lower intensity
behavioural treatment delivered by trained mental health clinicians
— Treatment of Addiction to Nicotine in Schizophrenia (TANS) or
Medication Management (MM) — in smokers with schizophrenia
who received NRT for 16 weeks and found no difference on absti-
nence (Williams et al., 2010). TANS was a high intensity treatment
of 24 sessions (45 minutes) delivered over 26 weeks and MM was
a moderate intensity treatment of nine sessions (20 minutes) deliv-
ered over 26 weeks that combined with NRT treatment significant-
ly reduced smoking consumption in smokers with schizophrenia
spectrum disorders. This study showed that mental health profes-
sionals can be trained to help smokers with schizophrenia spec-
trum disorders to maintain traditional cigarette abstinence.
Considering all these aspects, it is important to also investigate
harm reduction approaches for smokers with schizophrenia spec-
trum disorders.
Experiences of smoking cessation
A study conducted by Tulloch and collaborators (2016)
explored quitting experience and concerns of 732 smokers, 430
with psychiatric illness (18 with schizophrenia spectrum disor-
ders), in comparison with 302 without psychiatric illness.
Participants, enrolled between June 2010 and March 2013 to par-
ticipate in the FLEX (Flexible and Extended Dosing of NRT and
Varenicline in Comparison to Fixed-Dose NRT for Smoking
Cessation) trial, completed questionnaires assessing previously
used cessation aids and concerns about their upcoming quit
attempt. Smokers with schizophrenia spectrum disorders experi-
enced distress and negative affect as the most common predictors
of smoking relapse. The quit methods used by smokers with schiz-
ophrenia spectrum disorders were transdermal NRT (72.2%), fol-
lowed by NRT gum (11,1%), NRT lozenge (11,1%), NRT inhaler
(11,1%), varenicline (11,1%) and bupropion (11.1%) compared
with the following quit methods used by smokers without psychi-
atric illness: transdermal NRT (69.9%), followed by bupropion
(43.6%), NRT gum (32,9%), varenicline (19,3%), NRT inhaler
(12,9%), and NRT lozenge (8,2%).
Rae, Pettey, Aubry, and Stol, (2015) interviewed 16 partici-
pants with serious mental illness (six with schizophrenia spectrum
disorders) who had participated in a clinical trial comparing two
smoking cessation interventions, the first using NRT alone and the
second using NRT, motivational interviewing and a peer support
group. Findings from semi-structured interviews suggest smoking
cessation experiences were influenced by positive experiences of
NRT, though access to e-cigarettes or medications available in pill
form (e.g., varenicline and bupropion) were considered more
effective and easier to use. The intervention itself (such as the pres-
ence of smoking cessation aids and group support), Individual fac-
tors, (such as mental health, physical health, and substance use),
and social-environmental factors (such as difficult life events and
social relationships) influenced whether someone quit or not. The
authors acknowledged several limitations in their study such as the
small sample size, all participants coming from the same smoking
cessation intervention, the researcher not being blind to the smok-
ing cessation status of participants during the data collection and
analysis, the interpretative nature of the results and the fact that the
data were self-reported by participants and consequently subject to
the effects of recall and social desirability, and the use of the seven-
day period of abstinence and not continuous smoking abstinence
criterion to differentiate quitters from smokers. Also, the authors
did not differentiate the findings on the basis of the distribution of
the mental pathology enrolled in the study
(schizophrenia/schizoaffective disorder (n=6, 38%), depression
(n=5, 31%), bipolar disorder (n=4, 25%), and anxiety disorder
(n=1, 6%) and the thematic analysis did not give clear percentages
of responses but used vague terms such as “many” and “some”.
Knowles et al. (2016) qualitatively explored the experiences of
a small sample of 13 participants with serious mental illnesses, of
which eight had schizophrenia spectrum disorders, who used a
‘bespoke smoking cessation’ intervention, compared with their
experience of standard smoking cessation services. The authors,
without specifying if participants were in a stable or unstable phase
of their illness and without differentiating the findings on the basis
of diagnosis, enrolled five people with bipolar disorder and eight
with schizophrenia spectrum disorders). They found that this inter-
vention was perceived positively because the bespoke intervention
was more flexible and tailored compared with the previous stan-
dard smoking cessation programme.
In addition to the medication used, tailoring the smoking ces-
sation support to the individual needs of the smoker affected by
schizophrenia spectrum disorders may result in better outcomes. 
E-cigarettes for smoking cessation in people with
schizophrenia spectrum disorders
While the number of studies examining e-cigarettes for smok-
ing cessation in the general population is now fairly substantial,
despite mixed conclusions, there are far fewer studies relevant to
this topic that have been conducted with priority groups for smok-
ing cessation. This includes people with schizophrenia spectrum










disorders: the population that is the focus of this thesis. This sec-
tion reviews the existing published literature on this topic, firstly
outlining findings of studies that have examined e-cigarettes as an
intervention for smoking cessation in this group, and secondly out-
lining the prevalence and attitudes of people with schizophrenia
spectrum disorder regarding e-cigarettes. 
Interventional studies
A small uncontrolled study conducted at University of Catania
was the first study in the world to investigate the efficacy of e-cig-
arettes for smoking cessation/reduction in people with schizophre-
nia. In this early study, 14 smokers with schizophrenia spectrum
disorders not motivated to quit smoking were recruited. Fourteen
smokers were provided with an electronic cigarette kit and enough
cartridges to last up to12 weeks. They were advised to use the
product ad libitum throughout the day, not to exceed a four car-
tridge/day maximum as recommended by the manufacturer of the
product, a first generation “Categoria” e-cigarette, (Arbi Group
Srl, Milano, Italy) loaded with 7.4 mg nicotine cartridges called
“Original” cartridges. Participants were followed-up for one year.
At each visit, participant eCO levels were recorded, study diaries
were given to study personnel and unused study products were
turned in. Overall, this study found that at the 52-week visit, 50%
of smokers with schizophrenia who were provided with e-ciga-
rettes for 12 weeks had reduced their smoking by 50%, and a fur-
ther 14% had quit smoking completely with no increases in psychi-
atric symptoms (Caponnetto, Auditore, Russo, Cappello, & Polosa,
2013). These preliminary findings are noteworthy because none of
the participants initially sought treatment for smoking. However,
the study had a significant number of limitations, including the
absence of a control group and a very small sample size.
Subsequently, Pratt, Sargent, Daniels, Santos, and Brunette,
(2016) enrolled 21 outpatients with serious mental illness (schizo-
phrenia, schizoaffective disorder, or bipolar disorder) who smoked
at least 10 CPD, had a history of failed treatment-facilitated quit
attempts, and were not involved in smoking cessation treatment.
Participants were given second generation e-cigarettes (N-Joy
brand) based on each participant’s level of use of traditional ciga-
rettes and directions on how to use them, and were evaluated
weekly for one month. Authors declared that each e-cigarette car-
tridge was approximately equivalent to two packs of traditional
cigarettes but they didn’t mention the nicotine strength of the car-
tridges used in the study. Nineteen participants completed the
study visit (10 with schizophrenia spectrum disorders, nine with
bipolar disorder). The study found a significant smoking reduction
with a mean self-reported decline in use of traditional cigarette
from 192 to 67 cigarettes/week confirmed by CO reduction from
27 ppm to 15 ppm. There were some AEs reported: 58% of partic-
ipants experienced mild and transitory side effects, including
cough, dry/sore throat, nausea and dizziness. The study also exam-
ined participant’s perceptions. In answer to open-ended questions,
these smokers perceived e-cigarettes as enjoyable and satisfying,
and they were willing to buy e-cigarettes; they also perceived e-
cigarettes as healthier, useful to help them feel more accepted by
non-smokers, and useful to avoid the unpleasant odor of burned
cigarettes. In their conclusions Pratt et al. (2016) suggested that
people with serious mental illness may find e-cigarettes an appeal-
ing alternative to traditional cigarettes but recommended that fur-
ther RCTs with longstanding mental health conditions were need-
ed. In a more recent study, Hickling et al. (2018) conducted a 24-
week pilot study to investigate the efficacy of a six-week free first-
generation e-cigarette treatment to reduce traditional cigarette con-
sumption in 50 smokers with severe mental illness not motivated
to quit, including 42 (84%) participants with schizophrenia spec-
trum disorders. These smokers were offered free NJOY disposable
e-cigarettes with 4.5% nicotine and were encouraged to replace
traditional cigarettes with e-cigarettes as much as possible. A final
follow-up visit for assessment was scheduled at week 24. At the
end of the six-week free e-cigarette phase, 37% of participants had
reduced their tobacco consumption and 7% had stopped smoking.
Four weeks post this phase 26% of participants had reduced their
tobacco consumption and 5% had quit to smoke traditional ciga-
rettes. At final follow up (24 weeks), 25% of participants had
reduced their tobacco consumption and 2% had quit to smoke tra-
ditional cigarettes. This study found good product acceptability
and no negative impact on participants’ mental health or significant
AEs. However, the study had limitations, including that 16% of
participants with bipolar disorder had their psychopathological
changes assessed by the PANSS scale, which is designed to assess
schizophrenia spectrum disorder symptoms and not bipolar disor-
der symptoms. In addition, as the authors acknowledged, the study
was also limited by the fact that it involved the use of a first-gen-
eration e-cigarette, considered less effective in terms of blood
nicotine delivery, and the use of a self-report method for various
measures.
Prevalence and attitudes towards e-cigarettes in
people with schizophrenia spectrum disorders 
In addition to a small number of intervention studies, there are
also some data available on the extent to which schizophrenic
smokers use e-cigarettes and their attitudes towards these products.
For example, Miller, Wang, Wong, Paletta, and Buckley (2017)
investigated the prevalence and attitudes of e-cigarette use in the
USA amongst 60 inpatients and outpatients with schizophrenia or
schizoaffective disorder diagnosis. Participants completed an
anonymous, 10-minute, pencil-and-paper survey to evaluate the
prevalence of and attitudes toward e-cigarette use, and use of e-
cigarettes to help or hinder their psychopathology. The majority
(70%) of participants were current smokers, of whom 83% smoked
a mean of 15 CPD; 90% percent of participants were aware of e-
cigarettes, 37% had used them, 7% were current users and 24% of
never-users were considering using e-cigarette in the future. Thirty
four percent of surveyed smokers believed that the health effects of
e-cigarettes were less harmful than traditional cigarettes. Cost was
the most frequently mentioned potential disadvantage of e-ciga-
rettes (33%) and health improvements (39%), smoking reduction
(37%), and quitting (37%) were the most commonly mentioned
potential benefits. Smokers who were ever-users stated that tradi-
tional cigarettes were significantly more useful in reducing para-
noia, anxiety, depression, and reduced concentration, than e-ciga-
rettes. The authors suggested that e-cigarettes have modest signif-
icance to smoking cessation in smokers with schizophrenia spec-
trum disorders and concluded that their preliminary findings
should be investigated in larger samples.
Chen et al. (2016) conducted a survey of smoking cessation
treatment with 231 smokers with serious mental illness (33% with
schizophrenia/schizoaffective disorders, 63% with mood disor-
ders, 11% with post-traumatic stress disorder and eight percent
with borderline personality disorder), 45 psychiatrists and 97 case
workers in four community mental health centers in the USA. Fifty
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percent of smokers showed an interest in using e-cigarettes to quit
smoking and 22% reported current e-cigarette use. There were dif-
ferences between patient and provider perspectives: despite 82%
of patients reporting wanting to quit or reduce traditional cigarette
smoking, 91% of psychiatrists and 84% of case workers stated that
their patients were not interested in quitting; hence, psychiatric
treatment providers perceive their patients to have no motivation to
quit smoking. In contrast, their patients reported motivation to use
and active use of e-cigarettes to quit smoking.
Sharma, Wigginton, Meurk, Ford, and Gartner (2017) conduct-
ed a qualitative study to analyze Reddit online lay discussions and
assess motivations and limitations associated with e-cigarette use
amongst people with self-reported mental Illness, including nine
smokers with schizophrenia. Their thematic analysis included
3,263 comments from 133 discussion threads. Motivations to use
e-cigarettes amongst people with mental illness included self-med-
ication, quitting smoking, freedom and control, as a hobby, for
social connectedness and in response to caregivers and online
communities. Some limitations of e-cigarettes use included that
they were perceived to be an unsatisfactory substitute for tradition-
al cigarettes and psychiatric medicines, drug interactions, nicotine
addiction, risks of e-liquid, practical difficulties and cost. 
Conclusions
Studies found evidence suggesting that pharmacotherapy com-
bined with behavioural therapy for smoking cessation is effective
amongst smokers with schizophrenia spectrum disorders, although
more long-term research is required. This review summarised and
critically reviewed also studies on vaping as a smoking cessation
strategy for smokers with schizophrenia spectrum disorders.
Although e-cigarettes have not been proven to be totally safe, evi-
dence suggests that they may be less harmful alternatives to com-
bustible cigarette smoking. Consequently, e-cigarettes could be
considered as an applicable instrument for Tobacco Harm
Reduction (THR). Overall, there are very few studies of e-
cigarettes for smoking cessation in patients with schizophrenia and
these studies are very small. They have promising results, but more
research is needed. The findings from these studies, conducted
with first generation and second-generation e-cigarettes, suggests
that the provision of e-cigarettes can significantly reduce tradition-
al cigarette consumption and CO (Carbon Monoxide) expired
breath without significant variations of psychopathological signs
and symptoms and without showing significant and serious
Adverse Events (AEs). 
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